Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Evaluation of Sexual Function With Adjunctive Lumateperone in Patients With Major Depressive Disorder.
Journal: The Journal of clinical psychiatry
Published: September 03, 2026
Long-term safety and tolerability of lumateperone 42 mg in patients with stable symptoms of schizophrenia: Results from a 1-year open-label study.
Journal: Schizophrenia research
Published: April 16, 2026
Safety and Tolerability of Adjunctive Lumateperone for the Treatment of Major Depressive Disorder: A Pooled Analysis of Two Randomized Placebo-Controlled Trials.
Journal: CNS drugs
Published: March 13, 2026
Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial.
Journal: Neuropsychiatric disease and treatment
Published: January 30, 2026
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.
Journal: The American journal of psychiatry
Published: December 01, 2025
The efficacy of lumateperone across symptoms of a major depressive episode with mixed features in patients with major depressive disorder and bipolar disorder: Post hoc analyses.
Journal: Journal of affective disorders
Published: November 03, 2025
Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Published: September 10, 2025
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.
Journal: The Journal of clinical psychiatry
Published: August 28, 2025
Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial.
Journal: International clinical psychopharmacology
Published: July 22, 2025
Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study.
Journal: International clinical psychopharmacology
Published: July 15, 2025
Reply to Letter From Surekha et al: "Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions".
Journal: Journal of clinical psychopharmacology
Published: May 29, 2025
Last Updated: 09/26/2026